Institutional Investors Lead Shift in Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Sentiment

September 16, 2018 - By Sonya McDaniel

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

Sentiment for Algorx Pharmaceuticals Inc (NASDAQ:AGRX)

Algorx Pharmaceuticals Inc (NASDAQ:AGRX) institutional sentiment decreased to 0.7 in 2018 Q2. Its down -0.42, from 1.12 in 2018Q1. The ratio fall, as 14 institutional investors increased or started new holdings, while 20 sold and reduced their stakes in Algorx Pharmaceuticals Inc. The institutional investors in our partner’s database now possess: 15.95 million shares, down from 23.01 million shares in 2018Q1. Also, the number of institutional investors holding Algorx Pharmaceuticals Inc in their top 10 holdings decreased from 4 to 2 for a decrease of 2. Sold All: 12 Reduced: 8 Increased: 8 New Position: 6.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $12.45 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock decreased 25.36% or $0.123 during the last trading session, reaching $0.362. About 5.79M shares traded or 266.23% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 84.42% since September 16, 2017 and is downtrending. It has underperformed by 100.04% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on November, 5. They expect $-0.16 EPS, up 27.27 % or $0.06 from last year’s $-0.22 per share. After $-0.16 actual EPS reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Proquest Associates Iv Llc holds 3.85% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Investor Ab owns 3.51 million shares or 0.09% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.05% invested in the company for 3.53 million shares. The New York-based Needham Investment Management Llc has invested 0.03% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 86,792 shares.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $400 while the high is $800. The stock’s average target of $6 is 1557.46% above today’s ($0.362) share price. AGRX was included in 3 notes of analysts from March 29, 2018. As per Wednesday, May 9, the company rating was maintained by H.C. Wainwright. The company was maintained on Thursday, March 29 by Cantor Fitzgerald. Cantor Fitzgerald maintained it with “Buy” rating and $400 target in Tuesday, May 8 report.

More news for Agile Therapeutics, Inc. (NASDAQ:AGRX) were recently published by: Seekingalpha.com, which released: “Agile Therapeutics up 55% premarket” on September 11, 2018. Benzinga.com‘s article titled: “48 Biggest Movers From Yesterday” and published on September 12, 2018 is yet another important article.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.